Bioheart, Inc. Files With the FDA to Begin the ANGEL Trial

SUNRISE, Fla., Dec. 6, 2011 (GLOBE NEWSWIRE) -- Bioheart, Inc. (BHRT.OB) announced that they have completed an Investigational New Drug (IND) application to the FDA for the ANGEL trial. The clinical protocol is designed to assess the safety and cardiovascular effects of intramyocardial implantation of autologous adipose derived stem cells (LipiCell) in patients with chronic ischemic cardiomyopathy. Transplantation of LipiCell will be accomplished through endocardial implantations with the MyoStar™ Injection Catheter under the guidance of the NOGA® cardiac navigation system by Biosense Webster, Inc. – A Johnson & Johnson Company.